Yi Arnold


“Challenges in Biomanufacturing – from Human Tissue Processing to 3D printing of Bioactive Implants”


Yi Arnold, Ph.D. is the Director of Business Development and R&D of Theradaptive. Theradaptive is a regenerative medicine startup that has developed a platform for targeted delivery of potent regenerative therapeutics for tissue regeneration. Theradaptive is combining the latest 3D printing technology with its biologic delivery platform to design implants mimicking the native ECM for better and faster tissue repair and regeneration. Current programs include long bone repair, spine fusion, dental & CMF repair, and osteochondral repair. Prior to Theradaptive, Yi was a VP at Esco Venture, a Singapore-based Venture Capital group and a Director at Osiris Therapeutics, managing their wound care portfolio. Yi started her industry career at Kinetic Concepts, Inc. and has since developed and brought to market 3 human tissue-based products. Yi holds a BS in Mechanical Engineering, a PhD in Biomedical Engineering and received her postdoc training at Yale and Columbia University. Yi currently resides in Ellicott City, MD with her husband and two girls. She loves to run marathons in her spare time and is excited to be running the BMW Berlin Marathon in 2019!


To treat bone loss, autologous bone graft remains the gold standard due to its osteogenic, osteoinductive, and osteoconductive properties. However, autologous grafting is often associated with its limited availability, postoperative pain, and donor site comorbidity. This has led to the rise of many commercially available human tissue derived allogenic bone grafts. It is estimated that over 50% of bone-grafting cases utilize these products in the United States. Although providing a supporting matrix, most of these products have several disadvantages, among which are large inter- and intra-variabilities and high cost resulting from complex, labor-intensive, and error prone manufacturing processes. There is a significant need for bone grafts that can be manufactured in an automated, repeatable, and highly consistent manner. In this talk, I will discuss the challenges in manufacturing the current allogenic bone grafts. I will also describe how we combine 3D bioprinting, clinical imaging, osteoconductive bioink, and bioactive nanoparticle additives to create bioactive bone grafts that are scale-up ready, and can recapitulate key features of the native bone environment.